INTRODUCTION {#S1}
============

Elevated blood pressure (BP) is the leading modifiable risk factor for cardiovascular diseases and global burden of disease worldwide.^[@R1],[@R2]^ BP is also a classical complex genetic trait with an estimated heritability of 31%--68%.^[@R3]^ Although genome-wide association studies (GWAS) have identified over 120 genetic regions associated with BP,^[@R4],[@R5]^ the exact genomic mechanism underlying BP regulation remains to be clarified.

Reactive oxygen species (ROS), including superoxide anion (O2^−^), hydrogen peroxide (H~2~O~2~), and hydroxyl anion (OH^−^), play an important role in the pathogenesis of hypertension, as they could affect nitric oxide (NO) bioavailability, peroxynitrite (ONOO^−^) generation and redox senstive signaling pathyways.^[@R6]^ Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (Noxs) are major sources of ROS in cardiovascular and renal systems.^[@R7],[@R8]^ The classical Nox is a multicomponent enzyme comprised of the cytosolic subunits p40phox (*NCF4*), p47phox (*NCF1*), p67phox (*NCF2*), and Rac1 (*RAC1*) or 2 (*RAC2*), and the catalytic subunits p22phox (*CYBA*) and gp91phox (now referred to as *NOX2*).^[@R8]^ In mammalian, there are seven distinct NOX genes (*NOX1* to 5 and *DUOX1* and 2),^[@R9]^ and only *NOX1*, *NOX2*, *NOX4* and *NOX5* are identified in cardiovascular-renal systems and play an important role in renal and cardiovascular disease.^[@R7],[@R10]^

Extensive experimental data support the role of Noxs in BP regulation and pathogenesis of hypertension. In Ang II-infused rats and mice, expression and activity of Noxs, ROS generation and BP were increased.^[@R11],[@R12]^ In p47phox knockout mice, Ang II infusion failed to increase vascular O~2~^−^ production and hypertensive response was markedly blunted.^[@R13]^ In population studies, hypertensive patients have higher levels of plasma H~2~O~2~ and oxidative stress than normotensive individuals.^[@R6]^ Common genetic variants of *NOX4*, *CYBA* and *RAC1* have been reported to be associated with BP levels and hypertension.^[@R4]--[@R6],[@R14],[@R15]^ However, few studys have investigated the association of Nox related genes polymorphisms with BP changes and the risk of incident hypertension. In the current study we systematically selected 11 Nox related genes (*NCF2*, *RAC1*, *NOXA1*, *NOX4*, *NOX5*, *NOXO1, CYBA*, *NCF4*, *RAC2*, *NOX2*, and *NOX1*) and conducted single-marker and gene-based analyses to examine the associations of these genes with BP changes and hypertension among participants in the Genetic Epidemiology Network of Salt Sensitivity (GenSalt) study.

MATERIALS AND METHODS {#S2}
=====================

Study population {#S3}
----------------

The GenSalt study was conducted in a Han Chinese population from rural areas in northern China. The detailed information of the design and methods has been presented else where.^[@R16]^ Briefly, we used BP screening to identify potential probands among persons aged 18--60 years. Those with systolic BP (SBP) 130--160 mmHg and/or diastolic BP (DBP) 85--100 mmHg and no current or recent (less than 1 month before screening visit) use of antihypertensive medications as well as their offspring, siblings, spouses and parents were recruited in GenSalt study. Individuals with stage 2 hypertension, current use of antihypertensive medications, secondary hypertension, history of clinical cardiovascular disease, diabetes, chronic kidney disease, along with pregnant women, heavy alcohol users and those currently on a low-sodium diet were excluded from the study.

The GenSalt study was approved by Institutional Review Boards at all of the participating institutions in accordance with the Declaration of Helsinki. Written informed consents for the program were obtained from each participant.

Baseline data collection {#S4}
------------------------

The baseline examination was performed from 2003 to 2005. During the examination, information about family pedigrees, demographic characteristics, personal and family medical history, and lifestyle risk factors was obtained using a standard questionnaire which was administered by trained staff. In the morning of 3-day baseline observation period, nine BP measurements were obtained using a random-zero sphygmomanometer by trained technicians based on a standard protocol. Besides, before BP measurements, participants were advised to avoid coffee/tea, cigarette smoking, alcohol, and exercise. Mean BP was the average of nine BP measurements in the baseline period.

Follow-up data collection {#S5}
-------------------------

There were two follow-up examinations for GenSalt participants in 2008--2009 and 2011--2012. During each follow-up visit, a three-days examination was performed as that of the baseline period. Information on the history of hypertension and use of antihypertension medications was obtained using a standard questionnaire. Three BP measurements were obtained using a random-zero sphygmomanometer in the morning during each of 3 days of follow-up visits. The mean of the 9 BP measurements was calculated for the current analysis. Hypertension was defined as having a SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or use of antihypertensive medications.

Among 1,906 eligible individuals who participated in the GenSalt baseline examination, 117 individuals without BP data at both follow-up visits and another 21 individuals without genotype data were excluded. The remainning 1,768 participants (92.8%) were analyzed in the current study.

Genotype data and quality control {#S6}
---------------------------------

A total of 11 Nox related genes were selected and the detailed information of the genes has been presented elsewhere.^[@R15]^ Among 124 SNPs genotyped on the Affymetrix 6.0 platform (Affymetrix, Santa Clara, CA), 26 SNPs with low genotyping call rate (\< 95%), low minor allele frequency (MAF) \< 1%, or deviation from the Hardy-Weinberg equilibrium (HWE) were excluded. For the remaining 98 SNPs, we used Haploview software (version 4.2, <http://www.broad.mit.edu/mpg/haploview>) to select tag-SNPs with r^2^ \< 0.8.^[@R17]^ [Supplementary Table 1](#SD1){ref-type="supplementary-material"} presented the information of the final 52 tagged SNPs.

Statistical analysis {#S7}
--------------------

Quality control, including genotyping call rate, Mendelian consistency, MAF and HWE, was conducted by PLINK software (<http://zzz.bwh.harvard.edu/plink/>).^[@R18]^

Descriptive statistics were shown for the 1,768 participants. The additive association between SNPs and BP changes over time were assessed by mixed-effect linear regression models to account for the longitudinal, family-based design of the GenSalt study. Autoregressive and compound symmetry covariance matrices were used to account for the correlations of repeated measurements within individuals and of individuals within families, respectively. For the assessment of BP changes over time, the main effects of these variables and a genotype by follow-up time interaction term were included in the models. Briefly, genotype, follow-up time, a genotype by follow-up time interaction term, the fixed effects of baseline age, gender, and body mass index (BMI) were included in models using the PROC MIXED procedure in SAS (version 9.3; SAS Institute, Cary, NC).^[@R19]^ To account for the effects of antihypertensive medication, we conducted these analyses using imputed BP levels for participants taking antihypertensive medication by adding 10 and 5 mmHg to original SBP and DBP values, respectively.^[@R20]^ A sensitivity analysis was also conducted after excluding those participants taking antihypertensive medicine in the month prior to follow-up visit.

For examination of incident hypertension, 173 participants with hypertension at baseline were excluded. The additive associations between SNPs and incident hypertension were employed using generalized linear mixed models.^[@R21]^ Autoregressive and compound symmetry covariance matrices were once again used to account for the correlations of repeated measurements intraindividual and interindividuals within families, respectively. The baseline age, gender, BMI, and follow-up time were adjusted in the multivariable analysis by the PROC GLIMMIX procedure in SAS.

To validate our results from the mixed-effect models, we also used the R packages "kinship2" and "GWAF" to account for the genetic kinships among individuals (<http://www.r-project.org>). To account for the sex-specific structure genes (*NOX1* and *2*) on X chromosome, the models were assumed inactivation as well as not assuming inactivation. Gender-stratified analysis was also conducted for those SNPs located at the X chromosome.

Truncated product method (TPM) was performed for gene-based analysis of each Nox related genes (at least 2 SNPs were genotyped) with longitudinal BP changes and incident hypertension.^[@R22]^ In TPM, the *P*-values were estimated by 1,000,000 simulations with the truncation point as 0.10. We also employed the Versatile Gene-based Association Study (VEGAS) to evaluate the robustness of findings from the TPM.^[@R23],[@R24]^ The analysis was performed using the command line tool of VEGAS2 version 1.^[@R24]^

The false discovery rate method was used to adjust for multiple testing.^[@R25]^ More specifically, we used the PROC MULTTEST procedure, along with the false discovery rate option in SAS to calculate the Q values for single SNP-based and gene-based analyses. Q values less than 0.05 were considered statistically significant.

RESULTS {#S8}
=======

[Table 1](#T1){ref-type="table"} shows the characteristics of the 1,768 participants at baseline and two follow-up interviews. On average, study participants were 39.0 years old and had a BMI of 23.4 kg/m^2^, mean SBP of 116.9 mmHg and mean DBP of 73.8 mmHg at baseline. A total of 924 (52.3%) participants were male and 173 (9.8%) participants had hypertension at baseline. During a mean of 7.2-year of follow-up, the average SBP and DBP increased by 12.2 mmHg and 8.4 mmHg, respectively, and 512 (32.1%) participants free from hypertension at baseline developed hypertension.

[Figure 1](#F1){ref-type="fig"} and [Supplementary Table 2](#SD2){ref-type="supplementary-material"} show the associations of 52 SNPs in Nox related genes with BP changes and hypertension. SNPs rs12094228, rs16861188 and rs12066019 in *NCF2* were significantly associated with longitudinal changes in SBP (*P*~interaction~ = 1.1 × 10^−3^, 2.8 × 10^−3^ and 1.2 × 10^−3^, respectively) ([Table 2](#T2){ref-type="table"}). Each copy of the minor allele for marker rs12094228, rs16861188 and rs12066019 were associated with mean SBP increases of 0.26, 0.53 and 0.46 mmHg per year, respectively. SNPs rs12094228 and rs12066019 were nominally associated with longitudinal changes in DBP (*P*~interaction~ = 6.5 × 10^−3^ and 3.1 × 10^−3^, respectively). Similar results were obtained after including kinships between individuals by the packages kinship2 and GWAF. For longitudinal BP change, sensitivity analyses excluding those participants with antihypertensive medicine revealed similar results (data not shown). There are no statistically significant associations of rs12094228, rs16861188 and rs12066019 with the risk of incident hypertension.

[Table 3](#T3){ref-type="table"} presents the results of gene-based analyses. TPM and VEGAS have similar results and show that *NCF2* was significantly associated with SBP (*P*~TPM~ = 1.00 × 10^−6^, *P*~VEGAS~ = 1.26 × 10^−4^) and DBP changes (*P*~TPM~ = 5.84 × 10^−4^, *P*~VEGAS~ = 1.04 × 10^−3^). No genes was significantly associated with incident hypertension.

DISCUSSION {#S9}
==========

In this study, we investigated the association of the Nox related genes with longitudinal BP changes and incident hypertension among a large sample of Han Chinese population. We identified 3 novel *NCF2* SNPs that were significantly associated with longitudinal SBP changes after correction for multiple testing. The minor alleles of rs12094228, rs16861188 and rs12066019 were related to an increased SBP change over time. Consistent with these findings, gene-based analyses also revealed an association of *NCF2* gene with BP changes over time.

The p67phox coded by *NCF2* is a core cytosolic component of Nox. Several studies have shown physiological evidence of the association between p67phox and BP control.^[@R26],[@R27]^ For instance, in Dahl salt-sensitive (SS) rats, the higher expression of p67phox was associated with higher Nox activity and greater salt sensitivity; even with large increases of salt intake, suppression of p67phox produced significant reductions of hypertension, oxidative stress, and renal injury.^[@R26]^ Further functional study showed that the kidney of SS rats was particularly vulnerable to oxidative stress, and a reduction of Nox2 in SS rats with a null mutation of p67phox resulted in a significant reduction of oxidative stress from mitochondria in the renal medulla.^[@R27]^ In summary, these experiments demonstrated the role of p67phox in chronic BP regulation and salt sensitivity.

However, few studies evaluated the association between *NCF2* gene variants and longitudinal BP phenotypes. Our study provides the first evidence of an influence of *NCF2* gene on longitudinal BP phenotypes. The rs12066019 locates at 2kb upstream of *NCF2*, whereas rs12094228 and rs16861188 are in the intronic region. We used RegulomeDB, HaploReg and SNPinfo to speculate the functional implication of the significant SNPs.^[@R28]--[@R30]^ We found that rs12066019 locates at a potential transcription factor binding site for peroxisome proliferator-activated receptors (PPARs), which could regulate Nox activity and play an important role in the pathophysiology of hypertension.^[@R31]^ A PhenoScanner^[@R32]^ search of genotype-tissue expression(GTEx) project also showed that rs12066019 could affect the gene expression of *NCF2* in skin, esophagus mucosa and colon transverse, etc. However, further functional studies are necessary to investigate the role of rs12066019 in BP progression. From these web tools, little evidence showed that rs12094228 and rs16861188 are causally associated with the regulation of *NCF2* expression. In addition to the single-marker analyses, *NCF2* was aggregately associated with longitudinal BP changes in gene-based analyses. With similar gene-based results from both TPM and VEGAS, our findings highlight the gene-based analyses for increasing statistical power to investigate potential genetic mechanisms underlying BP regulation. Further genetic or functional research are needed to investigate the mechanism of *NCF2* in BP regulation.

A recent GWAS meta-analysis showed that the minor A allele of SNP rs2289125 in the *NOX4* gene was associated with lower pulse pressure (PP) (*P* = 9.1 × 10^−22^) in European ancestry and correlated with increased *NOX4* expression in endothelial cells;^[@R5]^ nevertheless, the association of rs2289125 with BP traits was not replicated in Asian.^[@R4]^ Although genotype data were not available for rs2289125 in GenSalt study, two SNPs near rs2289125 with maximum linkage disequilibrium (rs595518 and rs3017887, r^2^ = 0.283 and 0.28, respectively) were genotyped and not associated with SBP, DBP or PP in our analyses. Considering the different genetic background in East Asian and European and the inconsistent result from meta-analyses,^[@R4],[@R5]^ it is still uncertain whether rs2289125 is associated with BP traits in Chinese. Several studies showed that genetic variants in *CYBA* influenced the level of oxidative stress and were associated with hypertension.^[@R6],[@R14],[@R33]^ For example, C242T (rs4673) in *CYBA* was associated with hypertension in Caucasian.^[@R33]^ But only rs12709102 was available in the current study and in weak linkage disequilibrium with C242T (r^2^ = 0.02), we could not confirm the effect of *CYBA* gene C242T on hypertension in Chinese.

Strengths and limitations {#S10}
-------------------------

To our knowledge, this is the first study to examine associations of Nox related genes with BP changes and the risk of incident hypertension in a cohort study. Second, considering the homogeneity of the population in GenSalt study, the result is robust to population stratification. Besides, except for slightly younger (35.5 vs. 39.0 years), individuals included in this analysis (92.8%) are similar in distribution of gender and genotypes, BMI and BP compared with those dropped out ([Supplementary Table 3](#SD3){ref-type="supplementary-material"} and [4](#SD4){ref-type="supplementary-material"}). In addition, we used rigorous quality control procedures to ensure high quality genotype and phenotype data, including measurements of BP and covariates. Moreover, false discovery rate procedures were performed to account for multiple testing. However, there are several limitations in this study. The novel findings in our study need to be replicated in an external population with different genetic background. Furthermore, even though the Affymetrix 6.0 platform has good genomic coverage of common variants in the Han Chinese population,^[@R34]^ in this study we have limited genotype data in *CYBA* and *NOXA1* genes. Thus, researches are still needed to examine these genes in future. Finally, we do not provide in-vitro or in-vivo evidence for the biological function of these findings. Further studies are needed to investigate how the identified risk loci contribute to BP progression at the molecular and cellular level.

In conclusion, our study provided evidence that common variants of Nox related genes were associated with longitudinal BP phenotypes in Han Chinese. The Noxs are major sources of ROS in human vessels. Since polymorphic variants in Nox related genes may modulate ROS production and influence hypertension. The identification of polymorphisms in *NCF2* may be helpful to characterize patients with a genetically increased susceptibility to oxidative stree and hypertension, which is an important goal in human genetics research and the ear of precision medicine. However, replications of the findings in other populations are needed and functional studies are warranted to investigate the potential mechanism.
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###### 

Characteristics of 1,768 GenSalt follow-up study participants

                                                                 Baseline (N=1768)   Visit 1 (N=1687)   Visit 2 (N=1626)
  -------------------------------------------------------------- ------------------- ------------------ ------------------
  Age, years                                                     39.0±9.2            43.9±9.2           46.7±9.2
  Men, N(%)                                                      924 (52.3)          878 (52.0)         845 (52.0)
  BMI, kg/m^2^                                                   23.4±3.2            24.1±3.4           24.8±3.5
  SBP, mmHg                                                      116.9±14.1          122.4±16.8         129.1±17.3
  DBP, mmHg                                                      73.8±10.2           78.9±11.0          82.2±11.1
  Hypertension at baseline, N (%)                                173 (9.8)           \-                 \-
  Hypertension incidence, N (%)[a](#TFN2){ref-type="table-fn"}   \-                  264(16.6)          512(32.1)
  Follow-up time, years                                          \-                  4.6±0.7            7.2±0.9

Data are presented as mean ± SD or percentages. BMI, body mass index; DBP, diastolic blood pressure; N, number of participants; SBP, systolic blood pressure; SD, standard deviation.

Participants with hypertension at baseline were excluded.

###### 

Association of SNPs with BP changes and incident hypertension among GenSalt study participants

  gene     SNP          Chr   Position    Allele[a](#TFN4){ref-type="table-fn"}   SBP    DBP                                                 HTN                                            
  -------- ------------ ----- ----------- --------------------------------------- ------ --------------------------------------------------- ------ ------------------- ------------------- -------------
  *NCF2*   rs12094228   1     183547872   T/G                                     0.26   1.1x10^−3^ (0.03)[b](#TFN5){ref-type="table-fn"}    0.15   6.5x10^−3^ (0.14)   1.06 (0.87, 1.30)   0.55 (0.72)
           rs16861188   1     183553326   T/C                                     0.53   2.8x10^−3^ (0.049)[b](#TFN5){ref-type="table-fn"}   0.12   0.28 (0.61)         1.34 (0.90, 2.00)   0.15 (0.52)
           rs12066019   1     183561560   G/T                                     0.46   1.2x10^−3^ (0.03)[b](#TFN5){ref-type="table-fn"}    0.27   3.1x10^−3^ (0.14)   1.06 (0.73, 1.54)   0.77 (0.79)

Abbreviations: β, coefficient; Chr, chromosome; CI, confidence interval; DBP, diastolic blood pressure; HTN, hypertension; OR, odds ratio; *P*, raw *P*-values; Q, Q values; SBP, systolic blood pressure; SNP, single nucleotide polymorphism.

major allele/minor allele

False discovery rate Q values that are less than 0.05.

###### 

Gene-based associations of NADPH oxidase related genes with longitudinal BP phenotypes in the GenSalt study

  Gene[a](#TFN7){ref-type="table-fn"}   N    TPM                                          VEGAS                                                                                                                                         
  ------------------------------------- ---- -------------------------------------------- -------------------------------------------- ------ -------------------------------------------- -------------------------------------------- ------
  *NCF2*                                5    1.00×10^−6^[b](#TFN8){ref-type="table-fn"}   5.84×10^−4^[b](#TFN8){ref-type="table-fn"}   0.27   1.26×10^−4^[b](#TFN8){ref-type="table-fn"}   1.04×10^−3^[b](#TFN8){ref-type="table-fn"}   0.56
  *RAC1*                                10   0.07                                         0.30                                         0.27   0.20                                         0.19                                         0.20
  *NOX4*                                12   0.60                                         0.36                                         0.29   0.60                                         0.22                                         0.37
  *NOX5*                                2    0.07                                         0.04                                         0.01   0.04                                         0.02                                         0.01
  *NOXO1*                               3    0.22                                         0.26                                         0.19   0.60                                         0.38                                         0.48
  *NCF4*                                4    0.19                                         0.38                                         0.17   0.25                                         0.52                                         0.77
  *RAC2*                                8    0.03                                         0.09                                         0.27   0.02                                         0.23                                         0.16
  *NOX2*                                2    0.08                                         0.10                                         0.03   0.09                                         0.10                                         0.03
  *NOX1*                                4    0.18                                         0.19                                         0.03   0.35                                         0.86                                         0.05

Abbreviations: DBP, diastolic blood pressure; HTN, hypertension; N, number of tag SNPs; SBP, systolic blood pressure; TPM, truncated product method; VEGAS, versatile gene-based association study.

Genes containing at least 2 SNPs.

Significant after adjustment for multiple testing.
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